Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 telitacicept trial in active primary Sjögren’s disease
2026-525556-28-00Phase 3Authorised
- Sponsor
- Vor Bio
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Sjögren's syndrome comparing Telitacicept with Placebo (2 arms). Primary endpoint: Change from baseline in EULAR Sjögren’s Syndrome Disease Activity Index. Planned start Oct 2026; status: authorised.
02
Drugs
telitacicept
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on 2026-525556-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525556-28-00.